World Library  
Flag as Inappropriate
Email this Article

ARIAD Pharmaceuticals

Article Id: WHEBN0020737471
Reproduction Date:

Title: ARIAD Pharmaceuticals  
Author: World Heritage Encyclopedia
Language: English
Subject: Bcr-Abl tyrosine-kinase inhibitor, Bad Pharma, Aderis Pharmaceuticals, Zonite Products Corporation, Qualitest
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

ARIAD Pharmaceuticals

ARIAD Pharmaceuticals, Inc.
Type Public
Traded as NASDAQ: ARIA
Industry Pharmaceuticals, biotechnology
Founded 1991
Headquarters Cambridge, MA, United States
Key people Harvey Berger,
Chairman & CEO
Timothy P. Clackson,
President of Research and Development and Chief Scientific Officer
Products Ridaforolimus (Under development)
Ponatinib (FDA approved, trade name Iclusig)
AP26113 (Under development)
Revenue IncreaseUS$178.98M (FY 2010)[1]
Operating income IncreaseUS$104.90M (FY 2010)[2]
Net income IncreaseUS$85.25M (FY 2010)[3]
Total assets DecreaseUS$50.4M (FY 2010)[4]
Employees 125 (2011)
Website www.ariad.com

ARIAD Pharmaceuticals, Inc. is an oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On December 14, 2012 the FDA approved Ariad Pharmaceutical’s leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or unable to tolerate other tyrosine kinase therapies on the market.

Ariad has strong partnerships with Merck and is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. The company is also developing Iclusig for other blood cancers and solid tumors, such as gastrointestinal stromal tumors, acute myeloid leukemia, and certain forms of non-small cell lung cancer; and various investigator-sponsored trials in indications, including first line and second line CML, acute myeloid leukemia, non-small cell lung cancer, and medullary thyroid cancer. In addition, its product pipeline consists of AP26113, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus.

On February 21, 2014 Ariad Pharmaceuticals announced the appointment of Sarissa Capital’s Alexander J. Denner, Ph.D. to a two-year term on the Company’s Board of Directors. Previously, Dr. Denner served as a senior managing director at Carl Icahn's Icahn Capital and is currently Ariad’s second-largest shareholder.

On May 15, 2014, Ariad’s Board of Directors enacted an amendment to its Section 382 Rights Agreement allowing investment firm BlackRock, Inc. the right to acquire more than 4.99% of the common stock in the company.


Products

FDA-approved products

Products under development

See also

References

  1. ^ http://www.marketwatch.com/investing/stock/aria/financials
  2. ^ http://www.marketwatch.com/investing/stock/aria/financials
  3. ^ http://www.marketwatch.com/investing/stock/aria/financials
  4. ^ http://www.reuters.com/article/2010/05/10/idUS235987+10-May-2010+BW20100510

External links

  • Official ARIAD site
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.